Innate Pharma's IPH5201 Shows Encouraging Phase 2 Interim Results in NSCLC, Driving Continued Enrollment

summarizeSummary

Innate Pharma announced encouraging interim Phase 2 results for its IPH5201 in resectable non-small cell lung cancer, showing higher pathological complete response rates and leading to continued study enrollment.

check_boxKey Events

• Positive Phase 2 Interim Results

  Interim results from the MATISSE Phase 2 study of IPH5201 in combination with durvalumab and chemotherapy in resectable NSCLC showed higher pathological complete response (pCR) rates compared to a benchmark.

• Significant pCR Rates Observed

  pCR rates were 35.7% in patients with PD-L1 ≥1% and 50% in patients with PD-L1 ≥50%, indicating strong early efficacy signals.

• Study Continues Enrollment

  Based on these encouraging results, the MATISSE study will continue to recruit patients with tumors expressing PD-L1≥1%.

• Presentation at AACR 2026

  The interim results will be presented in a Clinical Trials Plenary Session at the American Association for Cancer Research (AACR) Annual Meeting 2026 on April 21.

auto_awesomeAnalysis

Innate Pharma reported positive interim data from its MATISSE Phase 2 study for IPH5201 in resectable non-small cell lung cancer (NSCLC). The drug, co-developed with AstraZeneca, demonstrated higher pathological complete response (pCR) rates compared to a benchmark, particularly in PD-L1 positive tumors. These encouraging early results are significant for a clinical-stage biotechnology company of this size, validating the potential of IPH5201 and supporting continued investigation. The presentation at a Clinical Trials Plenary Session at AACR 2026 further highlights the scientific community's interest in these findings, which could enhance investor confidence in Innate Pharma's pipeline.